Reaction to 'addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC'.
作者信息
Claassens Eva L, Ploumen Roxanne A W, van Nijnatten Thiemo J A, Smidt Marjolein L
机构信息
Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.
Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.
出版信息
Breast. 2025 Jun;81:104467. doi: 10.1016/j.breast.2025.104467. Epub 2025 Apr 4.
Abstract
摘要
相似文献
1
Reaction to 'addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC'.对“解决三阴性乳腺癌中导管原位癌对新辅助化疗反应研究的关键局限性”的回应
Breast. 2025 Jun;81:104467. doi: 10.1016/j.breast.2025.104467. Epub 2025 Apr 4.
2
Addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC.解决三阴性乳腺癌中导管原位癌对新辅助化疗反应研究中的关键局限性。
Breast. 2025 Jun;81:104466. doi: 10.1016/j.breast.2025.104466. Epub 2025 Apr 4.
3
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.预测三阴性乳腺癌新辅助化疗反应的基线因素及其对非手术治疗的影响。
Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.
4
The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis.新辅助化疗对三阴性乳腺癌患者导管原位癌的影响：一项全国性分析。
Breast. 2025 Apr;80:104425. doi: 10.1016/j.breast.2025.104425. Epub 2025 Feb 18.
5
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.托瑞帕利单抗联合化疗治疗转移性或复发性三阴性乳腺癌的TORCHLIGHT试验结果的通俗语言总结。
Future Oncol. 2025 Feb;21(4):421-429. doi: 10.1080/14796694.2024.2430106. Epub 2024 Dec 4.
6
Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.三阴性乳腺癌中 p53 表达对化疗预后和疗效的影响差异。
Breast Cancer Res Treat. 2018 Nov;172(2):437-444. doi: 10.1007/s10549-018-4928-2. Epub 2018 Aug 21.
7
The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer.治疗前活检中存在原位成分与乳腺癌新辅助化疗的反应无关。
Cancers (Basel). 2021 Jan 10;13(2):235. doi: 10.3390/cancers13020235.
8
Pathologic Response of Associated Ductal Carcinoma In Situ to Neoadjuvant Systemic Therapy: A Systematic Review.导管原位癌伴发癌对新辅助全身治疗的病理反应：一项系统评价
Cancers (Basel). 2022 Dec 20;15(1):13. doi: 10.3390/cancers15010013.
9
Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.新辅助化疗联合免疫检查点抑制剂治疗三阴性乳腺癌的疗效与安全性：一项随机对照试验的荟萃分析
Front Oncol. 2021 Nov 29;11:657634. doi: 10.3389/fonc.2021.657634. eCollection 2021.
10
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.乳腺癌新辅助化疗后的病理完全缓解和残留导管原位癌
Br J Cancer. 2006 Feb 13;94(3):358-62. doi: 10.1038/sj.bjc.6602950.
本文引用的文献
1
The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis.新辅助化疗对三阴性乳腺癌患者导管原位癌的影响：一项全国性分析。
Breast. 2025 Apr;80:104425. doi: 10.1016/j.breast.2025.104425. Epub 2025 Feb 18.
2
Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.新辅助全身治疗后乳腺癌患者导管原位癌反应评估的影像学发现：系统评价和荟萃分析。
Eur Radiol. 2023 Aug;33(8):5423-5435. doi: 10.1007/s00330-023-09547-7. Epub 2023 Apr 5.
3
Pathologic Response of Associated Ductal Carcinoma In Situ to Neoadjuvant Systemic Therapy: A Systematic Review.导管原位癌伴发癌对新辅助全身治疗的病理反应：一项系统评价
Cancers (Basel). 2022 Dec 20;15(1):13. doi: 10.3390/cancers15010013.
4
The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer.治疗前活检中存在原位成分与乳腺癌新辅助化疗的反应无关。
Cancers (Basel). 2021 Jan 10;13(2):235. doi: 10.3390/cancers13020235.
5
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.预测三阴性乳腺癌新辅助化疗反应的基线因素及其对非手术治疗的影响。
Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.
Zotero 插件